Product

Product

Product
Wisdom Product Active Pharmaceutical Ingredient

Active Pharmaceutical Ingredient

Active Pharmaceutical Ingredient

Commercial API

No.

API Product

CAS No

DMF/CEP

Standard

Indication

1

Benazepril HCl

86541-74-4

NMPA DMF: Y20190002852

DMF: 033744

CEP:2015-322

CDSCO

RC/BD-002644

USP/EP/Ch.P.

Cardiovascular

2

Tirofiban HCl

150915-40-5

NMPA DMF: Y20190006974

DMF: 032701

EU/ASMF/00701

In-house

Cardiovascular

3

Dronedarone HCl

141625-93-6

NMPA DMF:Y20220000297

DMF: 037247

CEP: 2022-277

USP/EP/Ch.P.

Cardiovascular

4

Eribulin Mesylate

441045-17-6

DMF:035523

EU/ASMF/00569

JP

Anti-Cancer

5

Ibrutinib(Form A&C)

936563-96-1

NMPA DMF: Y20230000804

DMF:038919

DMF:031917

In-house

Anti-Cancer

6

Alogliptin Benzoate

850649-62-6

NMPA DMF: Y20230001355

DMF:039984

In-house

Diabetes

7

Fosaprepitant Dimeglumine

265121-04-8

NMPA DMF: Y20200001493

DMF:035766

JP MF:304MF10040

In-house

Anti-Cancer

8

Aprepitant

170729-80-3

NMPA DMF: Y20200000221

DMF:033175

CEP:2019-117

JP MF:230MF10074

USP/EP

Anti-Cancer

9

Dapagliflozin

960404-48-2

NMPA DMF: Y20220000848

In-house

Diabetes

10

Entecavir

209216-23-9

NMPA DMF: Y20170000425

DMF:033104

CEP:2018-006

EP/USP

Anti-Virus

11

Gefitinib

184475-35-2

NMPA DMF: Y20200001369

CEP: 2022-291

EP

Anti-Cancer

12

Linagliptin

668270-12-0

DMF:031294

In-house

Diabetes

13

Fasudil HCl

105628-07-7

NMPA DMF: Y20220000495

JP MF:231MF10048

Ch.P./JP

Cardiovascular

14

Flurbiprofen Axetil

91503-79-6

NMPA DMF: Y20220000095

In-house

Analgesic

Polypeptide API

No.

API Product

CAS No

DMF/CEP

Standard

Indication

15

Difelikefalin Acetate

1024829-44-4

Validated

In-house

Antipruritic

16

Linaclotide

851199-59-2

In progress

In-house

IBS-C

17

Tirzepatide

2023788-19-2

In progress

In-house

Diabetes

18

Etelcalcetide HCl

1334237-71-6

In progress

In-house

SHPT

19

Semaglutide

910463-68-2

In progress

In-house

Diabetes

R&D API

No.

API Product

CAS No

DMF/CEP

Standard

Indication

20

Trabectedin

114899-77-3

In progress

In-house

Anti-Cancer

21

Lurbinectedin

497871-47-3

DMF:037624

In-house

Anti-Cancer

22

Baricitinib

1187594-09-7

DMF:036732

In-house

Rheumatoid Arthritis

23

Carfilzomib

868540-17-4

In progress

In-house

Anti-Cancer

24

Pralsetinib

2097132-94-8

In progress

In-house

Anti-Cancer

25

Exatecan Mesylate

169869-90-3

In progress

In-house

Anti-Cancer

26

Landiolol HCl

144481-98-1

In progress

In-house

Cardiovascular

27

Pentoxifylline

6493-05-6

In progress

In-house

Cardiovascular

28

Ozanimod HCl

1618636-37-5

In progress

In-house

Multiple Sclerosis

29

Enoxaparin Sodium

679809-58-6

In progress

In-house

Cardiovascular

30

Dalteparin Sodium

9041-08-1

In progress

In-house

Cardiovascular

31

Nadroparin Calcium

37270-89-6

In progress

In-house

Cardiovascular

32

Parnaparin Sodium

9041-08-1

In progress

In-house

Cardiovascular

33

Reviparin sodium

9005-49-6

In progress

In-house

Cardiovascular

34

Bemiparin Sodium

9041-08-1

In progress

In-house

Cardiovascular

35

Fondaparinux Sodium

114870-03-0

DMF:037499

In-house

Cardiovascular

  • APIs and intermediates covered by valid patents protection in the specific market shall only be used for the purpose of seeking regulatory approval and shall not be used to treat humans and animals for commercial purposes.
  • The advanced intermediates of all above APIs are available, with DMF support if required.

Related equipment

Stainless steel reaction kettle 1
Stainless steel reaction kettle 1
Stainless steel reaction kettle 2
Stainless steel reaction kettle 2
Centrifuge 1
Centrifuge 1
Centrifuge 2
Centrifuge 2
Double cone rotary vacuum dryer
Double cone rotary vacuum dryer
Airslide pulverizer
Airslide pulverizer
Solid feeder
Solid feeder
Non-clean production area 1
Non-clean production area 1
Non-clean production area 2
Non-clean production area 2